Background: Fosphenytoin, a phosphate ester prodrug of phenytoin, is metabolized to phenytoin in vivo. Phenytoin metabolites accumulate in renal insufficiency and cross-react in some phenytoin immunoassays. Our aim was to determine the accuracy of phenytoin immunoassays in renal patients treated with fosphenytoin. Methods: We measured phenytoin with HPLC and with the aca, ACS:180, TDx phenytoin II, Vitros, and AxSYM methods. Specimens were collected 2-120 h after fosphenytoin administration from 17 patients with renal insufficiency. Results: The AxSYM, TDx phenytoin II, ACS:180, and Vitros assays displayed falsely increased phenytoin results up to 20 times higher than the HPLC results. The aca Star results for these specimens were comparable to the HPLC results. Although fosphenytoin can crossreact with phenytoin immunoassays, no fosphenytoin was detected by a sensitive HPLC method in any sample that was tested for its presence. Conclusion: These results are consistent with the formation of one or more novel metabolites or adducts of fosphenytoin that accumulate in some critically ill patients with renal insufficiency and that display significant cross-reactivity with some, but not all, phenytoin immunoassay methods.
or intramuscularly. This inactive prodrug is rapidly metabolized to phenytoin by phosphatases present in liver, red blood cells, and other tissues (1 ). The in vivo conversion half-life is 5-15 min, and more rapid conversion is seen in patients with renal or hepatic diseases, presumably because of decreased protein binding of fosphenytoin (2, 3 ) . The cross-reactivity of fosphenytoin with phenytoin immunoassays is variable and can be clinically significant (4, 5 ) . Fosphenytoin is converted to phenytoin in vitro in serum and heparin-treated plasma samples, but is resistant to hydrolysis in EDTA plasma (6 ) . For therapeutic drug monitoring, phenytoin is quantified in serum or plasma. It is recommended that serum phenytoin concentrations should not be measured until at least 2 h after an intravenous (i.v.) dose of fosphenytoin and at least 4 h after an intramuscular dose (4 ) .
The phenytoin metabolites that accumulate in patients with renal failure [primarily 5-(p-hydroxyphenyl)-5-phenylhydantoin glucuronide (HPPH-G)] cross-react with some phenytoin immunoassays (7, 8 ) . However, the Emit, aca ® , ACS:180, TDx phenytoin II, and Vitros phenytoin assays are not affected by these metabolites (7) (8) (9) (10) . We report here an index case and six additional critically ill patients with renal insufficiency who received fosphenytoin and subsequently displayed falsely increased freeand total-phenytoin values by multiple immunoassay methods. These methods included some of the methods listed above that previously had been shown to be free of significant cross-reactivity with the phenytoin metabolites that accumulate in patients with renal failure.
Materials and Methods subjects
Subject 1 was a 54-year-old man who had a cerebrovascular accident, developed acute renal failure secondary to rhabdomyolysis, and was admitted to an intensive care unit. Shortly after admission, the patient had tonic-clonic seizures and was intubated, given an i.v. loading dose of both fosphenytoin and phenytoin, and started on i.v. phenytoin. He was dialyzed every other day beginning on Drug Monitoring and Toxicology hospital day 4 through hospital day 11. On hospital day 7, he was switched to i.v. fosphenytoin. This patient came to the laboratory's attention on hospital day 9, when it was noted that the concentration of non-protein-bound phenytoin (i.e., free phenytoin) was nearly equal to the total-phenytoin concentration. Within the clinical laboratory, total phenytoin was measured with the Emit method on the aca Star analyzer because of its reported specificity for phenytoin. In the absence of a commercially available Emit free-phenytoin assay, free phenytoin was measured on the Abbott TDx analyzer with TDx/FLx phenytoin or phenytoin II reagents. Although no longer commercially available, the phenytoin II reagents were used during this period because they had also been shown to be free from significant cross-reactivity with the HPPH-G metabolite of phenytoin. The temporal association of the discrepancy between total-and free-phenytoin measurements and the switch from phenytoin to fosphenytoin prompted us to evaluate several immunoassay methods for measuring total and free phenytoin in patients with renal insufficiency who were receiving fosphenytoin.
Subject 2 was a 68-year-old woman with a history of diabetes mellitus, hypertension, and degenerative joint disease who was admitted emergently for a thoracoabdominal aortic aneurysm repair. After surgery, she developed acute renal failure, seizures, hypotension, and metabolic acidosis. Subject 3 was a 55-year-old woman with a history of diabetes mellitus, hypertension, and end-stage renal disease who developed a subarachnoid hemorrhage and was admitted to the intensive care unit for mechanical ventilation. Subject 4 was a 70-year-old woman with a history of hypertension, end-stage renal disease, and a seizure disorder who was admitted with a Staphylococcus aureus graft infection; she subsequently developed sepsis, hypotension, and refractory seizures. Subject 5 was a 54-year-old man with a history of diabetes mellitus, hypertension, and end-stage renal disease who was admitted with orbital cellulitis; he subsequently developed sepsis and seizures, and required enucleation of the affected eye on hospital day 16. Subject 6 was a 31-yearold woman who developed gram-negative sepsis, alveolar hemorrhage, and acute renal failure 1 month post renal transplant. Subject 7 was a 33-year-old man with a history of hypertension, end-stage renal disease, and seizures who was admitted with a subarachnoid hemorrhage and hypertension.
apparatus
The TDx and AxSYM analyzers were from Abbott Laboratories, the aca Star analyzer was from Dade Behring, the Vitros 950 analyzer was from Ortho Clinical Diagnostics, and the ACS:180 analyzer was from Chiron Diagnostics. HPLC analyses for phenytoin were performed on a Hewlett-Packard series 1050 system. Centrifree ® micropartition devices with YMT membranes (Amicon) were used for ultrafiltration.
specimen collection and preparation
Fosphenytoin (50 g/L phenytoin equivalent) was obtained from Parke-Davis. All doses of fosphenytoin administered to patients are expressed in phenytoin equivalents. Serum or EDTA plasma samples were collected at least 2 h after an i.v. dose of fosphenytoin. Fosphenytoin was administered solely by the i.v. route in all study patients. All studies with human subjects were approved by the Institutional Review Board of the University of Mississippi Medical Center. Ultrafiltrates were prepared by centrifugation of ϳ1 mL of serum or plasma in a Centrifree device at 2000g for 20 min at ambient temperature.
assay procedures
Total and free phenytoin were measured by reversedphase HPLC using a validated procedure developed for the analysis of multiple anticonvulsant drugs (11 ) . Briefly, 0.1 mL of serum or 0.3 mL of ultrafiltrate was added to a conical polypropylene tube. Internal standard (alphenal in 100 L of acetonitrile) was added, and the tube was vortex-mixed briefly. After the addition of 100 L of 0.5 mol/L sodium phosphate buffer, pH 6.0, and 750 L dichloromethane, tubes were vortex-mixed for 10 s. After centrifugation, the upper aqueous layer was aspirated to waste and the solvent was evaporated under nitrogen. After the extract was reconstituted with 75 L of methanol and 500 L of water, 20 L was analyzed using a C 8 reversed-phase column with detection at 214 nm. The limit of quantification for phenytoin in serum was 0.2 mg/L.
Total fosphenytoin was measured by reversed-phase HPLC, as described previously (12 ) . Briefly, equal parts of internal standard [5-(p-methylphenyl)-5-phenylhydantoin] in water and concentrated phosphoric acid were added to serum or plasma. Fosphenytoin was extracted with diethyl ether, and the extract was dried under nitrogen and reconstituted with HPLC mobile phase. HPLC was performed using a 150 ϫ 3.9 mm C 18 column with a mobile phase consisting of 200 mL/L acetonitrile in deionized water containing 5 mmol/L tetrabutyl ammonium adjusted to pH 2.2-2.5 with phosphoric acid. The flow rate was 2.0 mL/min.
Abbott TDx/FLx phenytoin and phenytoin II reagents and calibrators were used to measure total and free phenytoin with a TDx analyzer. Abbott AxSYM reagents and calibrators were used to measure total phenytoin with an AxSYM analyzer. Chiron ACS:180 reagents and calibrators were used to measure total phenytoin with an ACS:180 analyzer. Dade/Behring aca phenytoin analytical test packs and calibrators were used to measure total phenytoin with an aca Star. Vitros reagent slides and calibrators from Ortho Clinical Diagnostics were used to measure total phenytoin with a Vitros 950 analyzer. All reagents were used according to manufacturers' instructions. data analysis EP Evaluator, release 3, software (David G. Rhoads Associates) was used for Deming regression analysis and calculation of r and S y͉x .
Results
Subject 1, whose phenytoin results first called the laboratory's attention to the discrepancy between immunoassays, had a free-phenytoin concentration measured by one immunoassay method (TDx phenytoin II) that was greater than the total measured by another immunoassay (aca Star). The dose and timing of phenytoin and fosphenytoin administration were reviewed, and it was noted that the free-phenytoin concentration was nearly equal to the total-phenytoin concentration 1 day after fosphenytoin administration was restarted. To further evaluate this unusual phenomenon, we quantified phenytoin concentrations in numerous serum or plasma samples by HPLC and five immunoassay methods. We also assayed fosphenytoin in some of these samples. The results, which are summarized in Table 1 , showed that the aca Star phenytoin results agreed with those obtained by HPLC, whereas the other immunoassays methods overestimated the true phenytoin concentration in samples collected after the administration of fosphenytoin. For the six additional patients who had renal insufficiency (creatinine Ͼ25 mg/L) with a concurrent major illness and who also received fosphenytoin, the phenytoin concentrations measured by several immunoassays were found to be significantly higher than the HPLC values (Tables 1-4 ). Of note, only four of these seven subjects survived their hospital stay.
Regression analysis of the immunoassay results vs HPLC are shown in Fig. 1 . The aca Star method compared well with HPLC (Fig. 1A) , whereas the other four immunoassay methods had high slopes and/or poor correlations, suggesting the presence of one or more crossreacting substances in the samples. In an attempt to quantify the magnitude of cross-reactivity in each immunoassay that was affected, we subtracted the HPLC result from each immunoassay result (designated ⌬) except for the aca Star and the results were subjected to regression analysis. There was poor correlation between ⌬ values except for the comparisons between the TDx phenytoin II and ACS:180 methods and the ACS:180 and Vitros methods. The elimination half-lives of any possible crossreacting substances were estimated in subjects 1, 3, and 5 after the discontinuation of fosphenytoin administration by plotting log⌬ vs time. The results are summarized in Table 5 . For each immunoassay method, the apparent half-life varied significantly between patients. For each individual patient, the half-life also varied, depending on the immunoassay method used. All four patients who had free-phenytoin concentrations measured had at least one result that was greater than the corresponding total result measured by either the HPLC or aca Star methods. When the free-phenytoin values obtained by HPLC were compared with those obtained with the TDx phenytoin II method, the immunoassay method was found to significantly overestimate the true free-phenytoin concentration (Fig. 2) . Furthermore, the correlation between the two methods was poor (r ϭ 0.559). In subject 7, free phenytoin was measured with the TDx phenytoin assay ( Table 4) . As was observed for the TDx phenytoin II, the free-phenytoin concentration measured with this method was greater than or equal to the total phenytoin measured by the HPLC or aca Star methods.
To confirm that the phenytoin metabolites that usually accumulate in renal insufficiency were not responsible for these falsely increased results, 24 samples from patients receiving phenytoin with renal insufficiency (creatinine, 15-92 mg/L) were assayed by the ACS:180, AxSYM, HPLC, and Vitros methods. The ACS:180 and Vitros methods provided results that were very close to HPLC values (Fig. 3, A and C) . These results are consistent with the previously reported minimal cross-reactivity of phenytoin metabolites with these two immunoassays. The AxSYM assay did demonstrate moderately increased results for some of these specimens (Fig. 3B) , presumably because of the known cross-reactivity of HPPH-G. However, the increases noted were not as great as those observed for the patients receiving fosphenytoin and could not account for all of the falsely increased results shown in Tables 1-4 .
Although all samples from the seven patients were collected at least 2 h after an i.v. dose of fosphenytoin and no residual fosphenytoin was detected in any of the samples tested, the cross-reactivity of fosphenytoin with each of the immunoassays used in this study was determined (Table 6 ). The aca Star and Vitros assays demonstrated similar low fosphenytoin cross-reactivity; the TDx, AxSYM, and ACS:180 showed intermediate cross-reactivity; and the TDx phenytoin II showed very high fosphenytoin cross-reactivity.
To determine whether all patients with renal insufficiency who received fosphenytoin had falsely increased phenytoin immunoassays results, we analyzed samples from 10 additional patients with renal insufficiency (creatinine, 24 -91 mg/L) who had received fosphenytoin, several of whom were critically ill. Comparison of the 
Discussion
In the present study, seven hospitalized patients with renal insufficiency who were receiving i.v. fosphenytoin had falsely increased total-and free-phenytoin results with several immunoassay methods. These falsely increased results could not be explained by the accumulation of phenytoin metabolites in patients with renal insufficiency because previous studies have shown that three of the affected phenytoin assays (TDx phenytoin II, ACS: 180, and Vitros) do not exhibit this problem (7, 8, 10 ) . These earlier studies included samples from critically ill patients, but no samples from patients receiving fosphenytoin. We also confirmed that the ACS:180 and Vitros assays do not cross-react with the phenytoin metabolites that accumulate in uremia, whereas the AxSYM method shows significant constant and proportional positive bias (Fig. 3) . We believe the falsely increased results may be caused by one or more substances that cross-react with some assay antibodies, and not chemical interference. The reason is that each one of the identified immunoassays utilizes a distinct analytical methodology. The Abbott AxSYM and TDx II methods are homogeneous assays that use fluorescence polarization. The ACS:180 method is a heterogeneous method that uses chemiluminescence. The Vitros method is heterogeneous and uses an enzymatic rate reaction monitored at 540 nm by reflectance spectrophotometry. The discrepant results between these immunoassays and HPLC are not caused by interference with phenytoin recovery in the HPLC. In the HPLC assay, which has been in clinical use for a long time, solvent extraction is used to isolate phenytoin from other potential interferences before analysis. The recovery of drugs using solvent extraction rarely is affected by the presence of other components in serum. The fact that the HPLC results correlate well with one immunoassay also argues against this because one would have to postulate identical decreases in two methodologically distinct assays.
The falsely increased results in the present study could not be explained by the cross-reactivity of residual fosphenytoin for the following reasons. First, samples were collected at least 2 h after i.v. administration of fosphenytoin, a more than adequate period of time for complete conversion of fosphenytoin to phenytoin. It is known that the half-life of fosphenytoin in patients with low albumin and uremia is decreased compared with healthy individuals; therefore, no residual fosphenytoin should be present in any samples collected in our study (2 ) . Second, no fosphenytoin was detected in any samples that were analyzed by a sensitive HPLC method (Tables 1 and 2 ). Third, the minimal degree of fosphenytoin cross-reactivity was similar for the aca Star and Vitros assays; however, the aca Star did not show falsely increased results, whereas the Vitros method did. If phenytoin metabolites and fosphenytoin are eliminated as causes of the falsely increased phenytoin immunoassay results, the presence of one or more novel cross-reacting fosphenytoin metabolites must be considered. These falsely increased results do not appear to be caused by an interfering substance because multiple immunoassays that use different methodologies (i.e., fluorescence polarization, chemiluminescence, and heterogeneous enzymatic methods) all show similar effects. Rather, one or more substances cross-react with each antibody used in the affected assays. Although we have yet to identify any novel cross-reacting substances, our data suggest that such substances could be metabolites or conjugates derived from fosphenytoin. The measured free-phenytoin concentration did not become greater than the total phenytoin in subject 1, who had been critically ill with renal failure, until 2 days after he was switched from phenytoin to fosphenytoin. We had been using the same total-and free-phenytoin assays for Ͼ2 years in critically ill patients and had not had any reports of problems until the pharmacy switched its i.v. phenytoin product to fosphenytoin. The first subject was identified ϳ1 month after this change. Fosphenytoin is thought to be dephosphorylated by tissue phosphatases to an intermediate that spontaneously hydrolyzes to phenytoin (13 ) . One possibility is that the intermediate forms an adduct with a metabolic product present in abnormally high concentrations in some critically ill patients with renal insufficiency. This hypothetical adduct is ultrafilterable and can cross-react with the free-phenytoin assays that were investigated.
The question may be posed as to why other institutions have not observed this same effect in patients receiving fosphenytoin. The answer may partly lie in the fact that during the time that we observed this novel cross-reactivity, different assays were in use for free phenytoin (fluorescence polarization immunoassay) and total phenytoin (Emit). The more-specific TDx phenytoin II assay was chosen for free-phenytoin measurement instead of the more widely used TDx/FLx phenytoin assay, which exhibits cross-reactivity with phenytoin metabolites. Many laboratories that perform both free-and total-phenytoin determinations are not likely to do this, choosing instead Samples collected from subjects 1 and 3 were analyzed for free phenytoin by HPLC and TDx phenytoin II assays. Deming regression analysis was performed (solid line); the dashed line represents an ideal comparison with a slope of 1.00 and an intercept of 0 (n ϭ 15; slope ϭ 3.01 Ϯ 1.21; intercept ϭ 2.14 Ϯ 1.22; r ϭ 0.559; S y͉x ϭ 2.86).
to use the same method for both free-and total-drug assays. A review of a recent College of American Pathologists proficiency testing survey revealed that 48% of respondents used either the Abbott AxSYM or TDx-TDx/ FLx methods for phenytoin (14 ) . The Abbott TDx freephenytoin assay was used by 82% of respondents. Both of these methods are subject to the cross-reactivity we have described. Therefore, falsely increased free-phenytoin results may not be readily recognized. Overestimation of total-and/or free-phenytoin concentrations in the serum by immunoassay methods can lead to significant underdosing of fosphenytoin, with consequent seizure activity. In fact, in our study, subjects 1, 3, 6, and 7 appear to have had their dosages of fosphenytoin reduced in response to falsely increased free-phenytoin concentrations measured by immunoassay. Of the immunoassays we investigated, only the aca Star total-phenytoin method, which is based on the Emit assay, correlated well with HPLC and was apparently unaffected.
It is noteworthy that different immunoassays quantify the cross-reacting substance or substances quite differently, as seen in Fig. 1 . The highly variable methoddependent half-lives observed after discontinuation of fosphenytoin (Table 5 ) might be explained by multiple cross-reacting species with different cross-reactivities in different phenytoin immunoassays. Possible alternative explanations might be that the concentration-response curve for a single cross-reacting species has a markedly different shape for each phenytoin immunoassay, or that the cross-reactivity might also depend on the concentrations of phenytoin present at the same time, as has been described for fosphenytoin and phenytoin metabolites (4, 8 ) . Some of the falsely increased results for subjects 1-7 in the AxSYM method can be attributed to the apparent cross-reactivity of HPPH-G with the AxSYM method in uremic patients (Fig. 3B) . This HPPH-G cross-reactivity leads to overestimation of the apparent cross-reactivity of any hypothetical fosphenytoin metabolites measured by the AxSYM method. The falsely increased results seen with the other phenytoin immunoassays presumably arise primarily from fosphenytoin metabolite cross-reactivity. Because our data demonstrate a lack of crossreactivity with the Emit antibody, this method is clearly preferred for total-phenytoin measurements. An investigation of the Emit reagents for the determination of free phenytoin as an alternative to HPLC is also warranted. The experiments reported here, using assays that do not cross-react with phenytoin metabolites that accumulate in uremia (primarily HPPH-G), demonstrate that one or more novel immunoreactive compounds can be found in serum specimens from some, but not all, patients with renal insufficiency receiving fosphenytoin. On the basis of our analysis of multiple samples from seven patients, the source of the cross-reactivity does not appear to be the prodrug fosphenytoin, but one or more as yet unidentified metabolites or adducts of fosphenytoin. None of the affected immunoassays require specimen extraction. Therefore, experimental protocols will have to be designed to isolate and identify any novel cross-reacting substances. Purification protocols using solid-phase extraction, solvent extraction, or antigen-antibody complex isolation may be successful approaches. Once any novel compounds are identified and assays for their quantification are developed, pharmacologic studies can be designed to assess their pharmacokinetic and pharmacodynamic properties. It may then also be possible to evaluate why one or more cross-reacting substances are observed only in certain patients, what additional factors might contribute to their effects, and whether these are all-ornone phenomena. At the present time, however, any such novel compounds are of interest primarily because of the analytical effects described in this report.
